Adagene presents results at esmo congress that show best-in-class therapeutic potential for anti-ctla-4 safebody® adg126 (muzastotug) in combination with keytruda® (pembrolizumab) in advanced/metastatic microsatellite-stable (mss) colorectal cancer (crc)

- confirmed partial responses (prs) doubled to four since asco gi in mss crc patients without liver and peritoneal metastases for overall response rate (orr) of 24% (4/17) with adg126 10 mg/kg every three weeks (q3w) in combination with pembrolizumab -
MSS Ratings Summary
MSS Quant Ranking